Masters of Longevity - The Pulse

Nature - Biotechnology23 Jul 2026
A novel small molecule remyelination therapy for multiple sclerosis (Nature - Biotechnology)

A novel small molecule remyelination therapy for multiple sclerosis

A research article describing a preclinical drug-discovery study that screened CNS-focused compounds and followed a lead through cellular and mouse remyelination assays.

Key takeaways
  • In terms of pharmacokinetics, CN045 is CNS-penetrable with low cytotoxicity.
  • CN045 has a short half-life in vivo.
  • Is an inflammatory-mediated demyelinating disease of the central nervous system (CNS).
Neuroscience News22 Jul 2026
Focused Ultrasound Delivers miRNA to Treat Glioblastoma (Neuroscience News)

Focused Ultrasound Delivers miRNA to Treat Glioblastoma

A news feature on a noninvasive MRI-guided focused ultrasound method for delivering RNA therapies into brain tumors, outlining the research approach and potential applications.

Key takeaways
  • New study utilizes MRI-guided focused ultrasound and microbubbles to open the blood-brain barrier non-invasively.
  • Approach could overcome many of the limitations of treatments using existing drugs.
  • Neuroscience News “This new approach could help target numerous molecules that promote cancer growth.
Science Daily - Health & Medicine22 Jul 2026
Lab-grown mini brains may predict which Alzheimer’s treatments will work (Science Daily - Health & Medicine)

Lab-grown mini brains may predict which Alzheimer’s treatments will work

Patient-derived lab-grown brain organoids and their secreted particles are used to investigate personalized responses to Alzheimer’s therapies, offering a glimpse into precision treatment prediction.

Key takeaways
  • Patient-derived brain organoids replicate patient-specific Alzheimer’s biology and show variable drug responses in vitro.
  • Proteomic analysis of organoids and their extracellular vesicles revealed early Alzheimer’s-related protein biomarkers.
  • Patterns in organoid-derived extracellular particles may help predict which Alzheimer’s treatments will be effective.
Fight Aging!22 Jul 2026
AICMLase Enzyme Developed to Break Down CML Advanced Glycation Endproducts (Fight Aging!)

CMLase Enzyme Developed to Break Down CML Advanced Glycation Endproducts

An article about a lab-developed enzyme designed to reverse a common age-related protein modification, explaining the research approach and implications.

Key takeaways
  • Researchers engineered CMLase via directed evolution from over 500 million variants to target CML modifications.
  • CMLase oxidizes Nε-carboxymethyl-lysine and restores the native lysine residue on affected proteins.
  • Enzyme reversed CML modifications in vitro and in human tissue samples from elderly donors.